Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMGN151 in Gynecologic Cancers
NCT07024784Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jul 2025
- Primary completion
- Jan 2028
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 3
01
Overview
A Phase 2 trial of opugotamig olatansine in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by AbbVie Inc.. Started Jul 2025; status: recruiting.
02
Drugs
opugotamig olatansine
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT07024784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07024784.